Published in Cancer Weekly, February 26th, 1996
The drug is marketed in the United States under the tradename Doxil. The CPMP recommended the use of the drug for both first-line and second-line treatment of AIDS-related Kaposi sarcoma (KS) in patients with low CD4 counts and extensive mucocutaneous or visceral disease. In addition, the CPMP recognized the use of Caelyx as a tradename...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.